vortioxetine and Renal-Insufficiency

vortioxetine has been researched along with Renal-Insufficiency* in 1 studies

Trials

1 trial(s) available for vortioxetine and Renal-Insufficiency

ArticleYear
Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine.
    Clinical pharmacology in drug development, 2018, Volume: 7, Issue:8

    Vortioxetine is an antidepressant agent with multimodal activity that is approved for the treatment of major depressive disorder at doses of 5 to 20 mg once daily. Vortioxetine is a medium-clearance drug that undergoes extensive metabolism via several cytochrome P450 isozymes. A series of single- and multiple-dose pharmacokinetic studies were performed to evaluate the impact of intrinsic (ie, subject-related) factors, such as age, sex, race, and renal and hepatic function, on the pharmacokinetics of vortioxetine. The point estimates on the ratios and their 90% confidence intervals (CIs) for the central values of AUC (area under the concentration-time curve) and C

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Dose-Response Relationship, Drug; Ethnicity; Female; Healthy Volunteers; Hepatic Insufficiency; Humans; Male; Middle Aged; Renal Insufficiency; Sex Factors; Single-Blind Method; Vortioxetine; Young Adult

2018